The global allergy diagnostics market appears to be consolidated. The leading companies discussed in the report include Quest Diagnostics, Inc., Omega Diagnostics Group Plc, Thermo Fischer Scientific, Inc., Siemens Healthineers, bioMérieux SA, HAL Allergy Group, and Stallergenes Greer. Transparency Market Research (TMR) finds that the allergy diagnostics market is rife with heightened levels of competition among the companies, owing to the presence of local as well as international players. Dominant players have been adopting the fruitful strategy of collaborating with leading companies.
The market for allergy diagnostics is projected to expand substantially at a CAGR of 12.8%, achieving US$3.8 bn by the end of 2024, which was estimated to be worth US$1.3 bn in 2015.
Low Cost of Consumables to Position them as Leading Product Segment
This 197 page report gives readers a comprehensive overview of the allergy diagnostics market. Browse through 30 data tables and 83 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/allergy-diagnostics-market.html
Allergy diagnostic consumables was the leading product segment in 2015 and is expected to continue to hold its dominance in the market over the coming period. Reagents and pipettes are some examples of consumables that have grown popular on account of their lower costs and high volume. The segment is expected to attain a 50.1% share by the end of 2024, with a remarkable CAGR of 13.6% between 2016 and 2024.
North America is expected to emerge as the dominant regional market for allergy diagnostics. However, Asia Pacific is projected to emerge as a rapidly growing market, with a remarkable CAGR of 13.6% between 2016 and 2024.
High Level of Pollution to Drive Growth
Lack of exposure to allergic elements in childhood and high levels of hygiene maintenance, particularly in the western countries, has contributed towards a rise in the demand for allergy diagnostics. Furthermore, factors such as longer duration of pollen seasons, climatic changes, high levels of air pollution on account of industrial and traffic smoke, increased tobacco smoking, and prevalence of other allergens in the environment are driving the market for allergy diagnostics. Moreover, genetic factors, increased vulnerability to allergies, and rise in healthcare expenditure are also boosting market growth. High prevalence of asthma among global population is also responsible for the rising demand for allergy diagnostics.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving allergy diagnostics market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5147
An important concept related to the expansion of the allergy diagnostics market is the “hygiene hypothesis”. This hypothesis proposes that little or no exposure to infectious agents during childhood makes a person more vulnerable to allergies, on account of early restriction on the development of the immune system. This is more prevalent in western countries, where hygiene is given utmost importance. The U.S., New Zealand, the U.K., and Australia showed 20 times higher incidence of allergies as compared to other countries in 2013. This tendency has been driving the growth of allergy diagnostics market in the west.
Regulatory Policies Will Pose a Major Threat to the Market
Strict regulatory policies, along with large investment costs, will pose as major challenges to the allergy diagnostics market. Also, the highly consolidated nature of the market will obstruct growth of new entrants. Currently, the leading market players are working on the reduction of costs in order to tap more profit. However, a rise in the types of allergies over the coming years will fuel the demand for allergy diagnostics. Changing food habits among people worldwide, coupled with growing popularity of processed and packed foods, are expected to furnish significant opportunities, by the end of 2024.
The information presented in this review is based on a Transparency Market Research report, titled, “Allergy Diagnostics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”
Inhalation and Nasal Spray Generic Drugs Market Report Overview – Key Futuristic Trends And Competitive Landscape 2023
The global inhalation and nasal generic drugs market features oligopolistic characteristic with a handful of players holding a majority share of the market, observes a new market study by Transparency Market Research (TMR). In 2014, Teva Pharmaceuticals Industries Ltd., Sandoz (Novartis AG), Mylan Laboratories, and Allergan plc held 45.9% of the revenue generated in the global inhalation and nasal spray generics market.
The manufacture of generic drugs is one of the key growth strategies that leading players are adopting to strengthen their positions in the market. This is to cater to untapped regions across the world that display growth potential of the inhalation and nasal spray generic drugs market. For instance, Asia Pacific holds promise for the market expansion of the companies involved.
The global inhalation and nasal spray generic drugs market is expected to be worth US$35 bn by 2023 increasing from US$23 bn in 2016 at a CAGR of 5.5% between 2015 and 2023.
This 100 page report gives readers a comprehensive overview of the inhalation and nasal spray generic drugs market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/inhalation-nasal-spray-generic-drugs.html
Introduction of Generic Drugs to Reduce Healthcare Costs in Asia Pacific
In terms of the drug class, combination sprays are expected to display the highest CAGR at 5.9% between 2015 and 2023.This is due to the high preference for combination sprays for COPD and asthma in most countries. The use of combination sprays and inhalers have proven to be highly effective for the treatment of serious respiratory diseases.
In 2014, North America and Europe stood as the largest markets for generic inhalers and nasal sprays and are expected to retain dominance in the coming years. The large-scale production and consumption of generic inhalers and nasal sprays coupled with strict regulations for patient safety are major factors for the dominance of these regional markets. On the other hand, Asia Pacific is expected to display the fastest growth in the inhalation and nasal spray generic drugs market. In this region, the rapidly evolving healthcare industry, increasing patient pool for asthma and COPD, and the highest population density are reasons for the increased focus of market players in this region. While China and Japan are expected to account for a majority consumption of generic inhalers and nasal sprays, Australia and India are expected to open lucrative growth opportunities to the market due to the increasing efforts from their governments to reduce overall healthcare costs.
Quality Considerations of Generic Drugs Necessitate Implementation of Production Standards in Developing Regions
Generic inhalers and nasal sprays require approval by the U.S. FDA prior to their commercial availability. Generic drugs are usually available at very low prices, thus it is adding the consumer base for these products.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving inhalation and nasal spray generic drugs market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1922
“Patent expiration of standard drugs is the primary reason for the increasing use of generic drugs, says a TMR analyst.” Generic drug manufacturers are reproducing standard drugs at very low prices due to the elimination of the need for marketing and advertising strategies, and most importantly, the elimination of the need for research and development.
The introduction of new generic drugs to the current mix of standard drugs will help reduce healthcare costs globally.
Quality considerations are becoming a concern for the growth of the inhalation and nasal spray generic drugs market in developing economies. The increasing number of drug manufacturers producing their own version of generic inhalers and nasal sprays has led to questions regarding the integrity of generic drugs.
The influx of generic drugs into commercial markets of developing regions has necessitated governments to implement standards for the production and sales of generic drugs. This could have an implication on the revenue generation of this market.
The review presented is based on the findings of a TMR research report, titled “Inhalation and Nasal Spray Generic Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”
The global smoking cessation and nicotine de-addiction products market is highly consolidated in nature with the top players boasting the majority stake in the revenue pie, states a research report by Transparency Market Research. At present, the prominent players such as Johnson & Johnson, Novartis, and GlaxoSmithKline collectively hold nearly 90% of the market. These players are focusing on developing innovations and new product launches in order to enhance their market penetration across the globe. Additionally, the global market is expected to witness a significant rise in the number of mergers and acquisitions by leading players to secure their leading position across the globe. According to the research study, the market opportunity for smoking cessation and nicotine de-addiction products is projected to reach a value of US$20,558.8 mn by the end of 2023.
This 82 page report gives readers a comprehensive overview of the smoking cessation and nicotine de-addiction products market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/smoking-cessation-nicotine-de-addiction-products.html
High Accessibility of Nicotine Replacement Therapy Products to Bolster North America Market
On the basis of geography, North America is expected to lead the global smoking cessation and nicotine de-addiction products market and account for a 41.5% share by the end of 2023. The growing awareness among consumers regarding smoking hazards and easy accessibility of nicotine replacement therapy (NRT) products are some of the primary factors augmenting the growth of the market in North America.
By type, the e-cigarette segment is predicted to grow robustly in the next few years and reach a value of US$16,474.6 mn by the end of 2023. Although e-cigarettes have been banned in several countries in Europe and Southeast Asia, this segment is predicted to witness high growth in the coming years.
Emergence of New Products to Benefit Global Smoking Cessation and Nicotine De-addiction Products Market
There has been a substantial rise in the cases of lung cancer and other cardiac and respiratory diseases due to cigarette smoking. The growing awareness concerning the health hazards is expected to drive the global smoking cessation and nicotine de-addiction products market in the near future. In addition, the intervention of government for encouraging smoking de-addiction such as a ban on smoking in public places and high taxes on cigarette products is indirectly promoting nicotine replacement therapy products, thus augmenting the growth of the market.
Furthermore, the introduction of new products and favorable reimbursement policies for smoking cessation therapy are anticipated to encourage the consumers to make more use of nicotine de-addiction products and accelerate the growth of the market in the near future.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving smoking cessation and nicotine de-addiction products market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1849
Low Awareness about Nicotine Replacement Therapy Products to Drag Down Market Growth
Regulations imposed by government for drugs and electronic cigarettes have restricted the growth of the smoking cessation and nicotine de-addiction products market across the globe. In addition, low awareness regarding nicotine replacement therapy products, especially in developing countries is another factor estimated to hamper the growth of the overall market in the next few years. Additionally, complex and rigid accreditation procedures are expected to suppress the growth of the market.
Nonetheless, the rising penetration of the global smoking cessation and nicotine de-addition products market in emerging countries is projected to offer lucrative growth opportunities for the key players in the market. Moreover, the rising focus of key players on research and development activities to introduce new products and create awareness about smoking hazards are anticipated to boost the demand in the coming years.
This information is based on the findings of a report published by Transparency Market Research, titled “Smoking Cessation and Nicotine De-addiction Products Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”
Non-Small Cell Lung Cancer Therapeutics Market: Snapshot
Non-small cell lung cancer (NSCLC) is the one of the commonest form of lung cancers. It is the most feared too. This is because it metastasizes into the bones and other tissues, making it tough to diagnose and treat it. In fact, almost 90% of all lung cancer cases are non-small cell lung cancer. Drugs meant to treat such a type of cancer range from regular regimens to targeted therapies. They are formulated leveraging simple chemistries to advanced complex proteins. The global market for non-small cell lung cancer therapeutics has seen robust growth due to the strong awareness among people about it. Another factor majorly contributing to the market is favorable government initiatives. Further, rapid approvals for drugs for non-small cell lung cancer by regulatory bodies and generous monetary assistance for research has also filliped the market.
This 94 page report gives readers a comprehensive overview of the non-small cell lung cancer therapeutics market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html
Despite the efficacy of targeted therapies and the uncovering of numerous molecular targets, the development of most drugs is in an early-stage pipeline. This, coupled with resistance to targeted therapies, is a major cause of worry in the non-small cell lung cancer therapeutics market.
The global non-small cell lung cancer therapeutics market was worth US$4.9 bn in 2014. Expanding at a CAGR of 12.1% from 2015 to 2023, it is slated to achieve a value of US$15.1 bn in 2023. The global non-small cell lung cancer therapeutics market is a fragmented with robust competition among the existing players that are both generic and branded companies. Some of the prominent names operating in the market are Bristol-Myers Squibb, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Inc., AstraZeneca plc, and Novartis AG.
Burgeoning Population to Propel Market in Asia Pacific
The global market for non-small cell lung cancer therapeutics comprises five key regions: North America, Europe, Asia Pacific, and the Rest of the World. Among them, North America leads with maximum share in market on account of the presence of a superior healthcare infrastructure and strong support by the U.S. federal government. In terms of growth rate, however, Asia Pacific is predicted to outshine all other regions owing to the burgeoning population, growing awareness about non-small cell lung cancer, increasing number of government projects pertaining to lung cancer, and ongoing efforts for timely intervention.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving non-small cell lung cancer therapeutics market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504
Effectiveness of Angiogenesis Inhibitor Drives Growth
The global market for non-small cell lung cancer therapeutics market can be segmented on the basis of drugs into EGFR inhibitor, angiogenesis inhibitor, microtubule stabilizer, kinase inhibitor, folate antimetabolites, and PD-1/PD-L1 inhibitor. At present angiogenesis inhibitor, also known as anti-angiogenics that thwart formation of new blood vessels, dominates the market. Going forward too, it is likely to retain its leading position because of the strong demand for this efficacious, targeted therapy in the crucial Europe, Japan, and the U.S. markets. Avastin, a type of angiogenesis inhibitor, is predicted to see maximum uptake. Exhibiting a CAGR of 1.8% from 2015 to 2023, the angiogenesis inhibitor segment is predicted to attain a market value of US$ 2,020.4 mn by 2023.
The folate antimetabolites segment trails the angiogenesis inhibitor segment in the global non-small cell lung cancer therapeutics market. The EGFR inhibitor and microtubule stabilizer segments come in third and fourth positions in terms of market share. The PD-1/PD-L1 inhibitor will likely outpace all other segments vis-à-vis growth in the upcoming years due to the effectiveness of the treatment, which has been corroborated by clinical data that shows double survival rate. Unveiling of new targeted therapies with more surveillance rate could, however, hobble the growth in the market.
The looming patent expiry of blockbuster drugs and the need for maintaining the flow of novel therapeutics have led to realization that pharmaceutical companies cannot allow the status quo to remain as it is. Collaborating with other key players has thus become a popular strategy among leading enterprises vying to benefit from a stronger product pipeline.
As per Transparency Market Research, Sanofi, Roche, Novartis, and Pfizer dominated the global hospital pharmaceuticals market in 2014, collectively holding a share of 18.6%. Among these companies, Novartis held the dominant share of 5.5% in the global market, followed by Pfizer that held 4.8% share in the global market.
Developing Economies to Exhibit Lucrative Opportunities
Developing economies are expected to report the most lucrative prospects for these companies. Lower pricing therefore could be of advantage for enterprises seeking to expand their operations. TMR recommends that focusing on value adding activities could reduce operational cost incurred by a pharmaceutical company and improve its process efficiency.
This 192 page report gives readers a comprehensive overview of the hospital pharmaceuticals market. Browse through 12 data tables and 43 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/hospital-pharmaceuticals-market.html
The global hospital pharmaceuticals market is expected to gain significantly from the increasing emergency visits. As told by TMR’s lead analyst, “The rate of emergency department visits has outpaced growth reported by the hospital pharmaceuticals market in the last decade, which has significantly contributed in boosting sales of specialty drugs.” “The increasing spending on nominal drugs, combined with rising per capital healthcare expenditure, is expected to positively influence the market’s trajectory,” he added.
Market to Gain Impetus from High Prevalence of Chronic Ailments
Besides this, the high prevalence of chronic ailments worldwide is also likely to fuel demand from the global hospital pharmaceuticals market. The increasing prevalence of these diseases is primarily contributed by the changing lifestyle, rising geriatric population, and excessive addition to tobacco and alcohol.
The market is also expected to significantly gain from the increasing trend of using telemedicine technology. However, the impending patent expiry of blockbuster drugs is likely to impact the market negatively. The rising trend of home healthcare will also negatively influence the market’s trajectory in the near future. Entry of generic drug producers also pose a threat to the companies operating in the global hospital pharmaceuticals market.
Nevertheless, the extensive research and development activities undertaken by key players and research organizations are expected to boost prospects for the market in the near future. Opportunities for the market is also expected to bolster with the increasing construction of hospitals and the rising healthcare spending worldwide.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving hospital pharmaceuticals market during 2015 – 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3535
North America to Emerge as Dominant Regional Market
Regionally, the opportunities for the global hospital pharmaceuticals market seem the most lucrative in North America. As per TMR, the North America hospital pharmaceuticals market is expected to surge at a CAGR of 3.4% between 2015 and 2023. The region held a dominant share of 57.5% in the global market in 2014. Europe is likely to emerge as the second-largest market for hospital pharmaceuticals during the same forecast period.
In the meantime, the increasing opportunities in Asia Pacific and Latin America will compel leading vendors to shift their focus from developed to developing economies. The large population base in Asia Pacific and the increasing investment on the healthcare sector will boost opportunities for the hospital pharmaceuticals market in the region.
As per TMR, the global hospital pharmaceuticals market is expected to surge at a CAGR of 3.9% between 2015 and 2023. The market stood at US$197.3 bn in 2014 and is expected to reach US$280.3 bn by the end of 2023.
This review is based on information published by Transparency Market Research in a report, titled “Hospital Pharmaceuticals Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023.”